CLINICAL AND MOLECULAR BIOLOGICAL PROGNOSTIC FACTORS IN PATIENTS WITH MALIGNANT BRAIN GLIOMAS

Background. The analytic findings concerning 3-year cumulative survival of patients with malignant brain gliomas are presented, depending on IDH1 gene mutation status, tumor grade (Grade II) and patient's age. Purpose. To study cumulative survival of patients with malignant brain gliomas depending on IDH1 gene mutation status, tumor grade (Grade II) and patient's age for prediction of the disease course. Material and methods. The disease specific 3-year cumulative survival of 95 patients with malignant brain glioma treated at N.N. Alexandrov National cancer Centre in 2009–2014 was evaluated with the Kaplan-Meier method calculating standard error (Se). The age-related survival was assessed using univariate Cox proportional hazards regression. The data were processed in statistical R package, version 3.4.2 using Survival Library. Results: According to the analytic findings, the favourable prognostic factors in patients with malignant brain glioma are patient's age younger than 45 years, low tumor grade (Grade II) and the presence of mutation in IDH1 gene. Conclusions. The factors influencing the survival of patients with malignant brain gliomas are the tumor grade (Grade), the mutational status of IDH1 gene, the patient's age.